Citicoline Injection 1g/4ml GMP Grade (finished medicine, drugs, pharmaceutical)

Transport Package: Box Package
Specification: citicoline 1g/4ml
Gold Member Since 2021

Suppliers with verified business licenses

Trading Company

Basic Info.

Model NO.
1g/4ml
HS Code
3004
Production Capacity
1, 000, 000 Boxes

Product Description

Product information
Product name: Citicoline injection
Specification: 1g/4ml
Package: 5 ampoules/tray/box
Shelf life: 36 months

1 What CITICOLINE injection is and what it is used for

PHARMACOLOGICAL PROPERTIES:
PHARMACODINAMICS
Citicoline, being the precursor of key ultrastructural components of a cellular membrane (mainly phospholipids), possesses wide range of activities, promotes restoration of the damaged cell membranes, inhibits action of phospholipases, what prevents excessive formation of free radicals and destruction of cells, affects the mechanisms of apoptosis. In the acute period of stroke it reduces the volume of damaged tissue, improves cholinergic transmition. In head injury it reduces duration of a post-traumatic coma and intensity of neurologic symptoms. Citicoline improves observed during hypoxia symptoms, such as memory impairment, emotional liability, lack of initiative, difficulties at conducting of daily actions and self-service. The drug product does not influence breath, pulse and arterial pressure; therefore long treatment is possible. 

PHARMACOKINETICS
As Citicoline is natural compound which is found in organism, it is impossible to provide classical pharmacokinetic research in connection with complexity of quantitative analysis of exogenous and endogenous 
Citicoline.

INDICATIONS:
1. Disturbance of consciousness associated with head injury or brain surgery.
2. Promotion of rehabilitation of the upper extremities in patients with hemiplegia following cerebral apoplexy.
3. Treatment in combination with anticholinergics in the following cases of parkinson's disease, in which tremor is especially severe:
- Cases in which adverse reactions have developed under treatment with L-DOPA.
- Cases in which the administration of L-DOPA is difficult because of laparotomy or complication.
- Cases in which L-DOPA is ineffective.
4.Concomitant therapy with protease inhibitors in the treatment of the following diseases:
- Acute pancreatitis.
- Acute exacerbation of chronic recurrent pancreatitis.
- Acute pancreatitis after surgery.

If you are interested in our products,ple feel free to contact us:
Clara 
 
 

Send your message to this supplier

*From:
*To:
*Message:

Enter between 20 to 4,000 characters.

This is not what you are looking for? Post a Sourcing Request Now

You Might Also Like

Gold Member Since 2021

Suppliers with verified business licenses

Trading Company
Number of Employees
11
Year of Establishment
2014-04-04